Social Media and Cancer Screening Information

NORC/AmeriSpeak will recruit participants who meet the study criteria and invite them to complete a 15-minute survey. Participants will be randomly assigned to one of five conditions, with approximately 400 people in each condition, and will respond to various questions after viewing the study messaging. Once 2,000 participants complete the survey, the data will be de-identified and provided to the study team for analysis.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Behavioral: Control; Behavioral: Median Ranked Cancer Screening Messaging; Behavioral: Overall Preferred Cancer Screening Messaging; Behavioral: Black American Preferred Cancer Screening Messaging; Behavioral: White American Preferred Cancer Screening Messaging

Detailed Description

NORC/AmeriSpeak will put all of the study content into their system. They will send out the opportunity to participate in the study, which should take about 15 minutes, to people in their panel who meet our participation criteria. Participants will be directed to the study information sheet that includes all elements of consent. Participants who agree to participate will start the survey experiment. The survey experiment will randomize participants into one of five conditions: (1) control (no exposure), (2) overall median ranked messages (from the prior study), (3) messages preferred by all participants, (4) messages preferred by Black American participants, and (5) messages preferred by White American participants. Approximately 400 people will complete each condition. After viewing the study stimuli (or no stimuli in the control condition), participants will respond to various outcomes and other variables of interest (see questionnaire draft included). After all 2,000 people have completed the study, the study team will receive a de-identified data file from NORC/AmeriSpeak with all study data and engage in analysis. This study is planned to close the study around that time as the study team completes data analysis and write-up the findings.

• Study Type: Interventional
• Enrollment (Actual): 2030
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Andy King

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Identify as white/Caucasian or Black/African American.

Exclusion Criteria:

• Do not identify as white/Caucasian or Black/African American.
• Previously diagnosed with colorectal cancer
• Non-English speakers

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control (no exposure); Participants in the Control Arm will not be shown any messages.	Behavioral: Control; There will be no message content of cancer screening and sharing intentions in this arm.
Experimental: Median Ranked; Participants in the Median Ranked Arm will be shown four Median Ranked messages.	Behavioral: Median Ranked Cancer Screening Messaging; Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
Experimental: Overall Preferred; Participants in the Overall Preferred arm will be shown four Overall Preferred messages.	Behavioral: Overall Preferred Cancer Screening Messaging; Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
Experimental: Black American Preferred; Participants in the Black American Preferred arm will be shown four Black American Preferred messages.	Behavioral: Black American Preferred Cancer Screening Messaging; Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
Experimental: White American Preferred; Participants in the White American Preferred arm will be shown four White American Preferred messages.	Behavioral: White American Preferred Cancer Screening Messaging; Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intentions to Adhere to Colorectal Cancer Screening (CRCS) Recommendations	After reading cancer screening (CRCS) recommendations, this outcome will assess how likely they are to follow on the the screening recommendations. Response options: Very unlikely (1), unlikely, neither unlikely nor likely, likely, very likely (5) A higher score indicates a favorable outcome, and a lower score indicates a less favorable outcome.	15 minutes
Intentions to Adhere Test Preference Indication	To determine which colorectal cancer screening (CRCS) participants are most likely to choose. Response options: stool-based tests (e.g., FOBT or FIT); endoscopic/scoping approach (e.g., colonoscopy or sigmoidoscopy); whatever my doctor recommends to me; something other than a stool-based or scoping approach; I would not follow the recommendations. This outcome will report the count of responses.	15 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Likelihood of Sharing Information Via Social Media	This outcome measure will determine how likely participants are to share the messages about colon cancer screening on social media. Response options: Very unlikely (1), unlikely, neither unlikely nor likely, likely, very likely (5) A higher score indicates a favorable outcome, and a lower score indicates a less favorable outcome.	15 minutes
Information Sharing Behavior	This outcome will report the count of participants will seek more information after the study. The participants will be asked a question on if they would like more information (Yes/No) and survey vendor will track participants who click a link to an external resource like the American Cancer Society to learn more.	15 minutes

Collaborators and Investigators

• Sponsor: University of Utah
• Collaborators: National Cancer Institute (NCI); AmeriSpeak - NORC
• Investigators: Principal Investigator: Andy King, PhD, Huntsman Cancer Institute/ University of Utah

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2025
• Primary Completion (Actual): January 21, 2025
• Study Completion (Actual): January 21, 2025

Study Registration Dates

• First Submitted: November 19, 2024
• First Submitted That Met QC Criteria: November 27, 2024
• First Posted (Actual): December 2, 2024

Study Record Updates

• Last Update Posted (Actual): March 20, 2026
• Last Update Submitted That Met QC Criteria: March 18, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Colorectal Neoplasms
• Other Study ID Numbers: HCI183491; 5R37CA259156-04 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified data will be shared/uploaded to an online data repository like OSF.
• IPD Sharing Time Frame: Once the primary results are published in a peer-reviewed journal article, the de-identified data will be published in an online data repository. The data will then be available for as long as the online repository is available
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No